The effect of adding N-acetylcysteine ??to the usual treatments of schizophrenia in improving the symptoms in patients referred to the ward and clinic of Khorshid Hospital in 1401

The effect of adding N-acetylcysteine ??to the usual treatments of schizophrenia on the positive, negative and cognitive symptoms of patients with schizophrenia admitted

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201119049445N2

Enrollment

Registered

2022-06-09

Start date

2022-06-21

Completion date

Unknown

Last updated

2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with schizophrenia who have undergone an acute phase. Schizophrenia

Interventions

Intervention 1: Intervention group: N-acetylcysteine ??at a dose of 600 mg daily in effervescent tablets for two months. Intervention 2: Control group: One placebo daily for two months.

Eligibility

Sex/Gender

All

Age

19 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients with schizophrenia between the ages of 19 and 65 who have undergone the acute phase (the onset of the acute phase is assessed by a psychiatrist and the project resident) Diagnosis of schizophrenia based on DSM 5 criteria by a psychiatrist Have at least five classes of education

Exclusion criteria

Exclusion criteria: Pregnancy and lactation Substance abuse Severe physical illness Contraindications to the use of N-acetylcysteine Existence of intellectual disability Receive ECT 6 months before or during the study Patients treated with nitroglycerin Patients treated with insulin Patients treated with chloroquine Patients treated with more than 200 mg of selenium Patients treated with anticoagulants except aspirin and NSAIDs

Design outcomes

Primary

Measure	Time frame
Improve cognitive function. Timepoint: Before the start of the study and 4, 8 weeks after taking N-acetylcysteine. Method of measurement: Average total score of NUCOG questionnaire and its areas.;Improve the negative symptoms of schizophrenia. Timepoint: Before the start of the study and 4, 8 weeks after taking N-acetylcysteine. Method of measurement: Scale for the Assessment of negative Symptoms.;Improve the positive symptoms of schizophrenia. Timepoint: Before the start of the study and 4, 8 weeks after taking N-acetylcysteine. Method of measurement: Scale for the Assessment of Positive Symptoms.	—

Measure

Time frame

Improve cognitive function. Timepoint: Before the start of the study and 4, 8 weeks after taking N-acetylcysteine. Method of measurement: Average total score of NUCOG questionnaire and its areas.;Improve the negative symptoms of schizophrenia. Timepoint: Before the start of the study and 4, 8 weeks after taking N-acetylcysteine. Method of measurement: Scale for the Assessment of negative Symptoms.;Improve the positive symptoms of schizophrenia. Timepoint: Before the start of the study and 4, 8 weeks after taking N-acetylcysteine. Method of measurement: Scale for the Assessment of Positive Symptoms.

—

Secondary

Measure	Time frame
Peripheral blood glutathione leve. Timepoint: Before the intervention and two months after the intervention. Method of measurement: Blood sampling and measurement of glutathione levels with glutathione assy kit.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHajar Salimi

Esfahan University of Medical Sciences

salimi85ha@gmail.com+98 31 3670 0517

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026